Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review4119 has been discontinued.
View all Glutamate (Metabotropic) Group III Receptors products.Cinnabarinic acid is a mGlu4 receptor agonist. Activates mGlu4 receptors in transiently transfected HEK293 cells; selective over all other mGlu subtypes (mGlu1, mGlu2 and mGlu5-8). Decreases cAMP levels in native cultured cerebellar granule cells. Also counteracts excitotoxic neuronal cell death induced by NMDA in mixed cultures of cortical cells; displays neuroprotective activity.
分子量 | 300.22 |
公式 | C14H8N2O6 |
储存 | Store at -20°C |
纯度 | ≥98% (HPLC) |
CAS Number | 606-59-7 |
PubChem ID | 114918 |
InChI Key | FSBKJYLVDRVPTK-UHFFFAOYSA-N |
Smiles | O=C2C(N)=C(C(O)=O)C1=NC3=C(C=CC=C3C(O)=O)OC1=C2 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Fazio (2012) Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type-4 metabotropic glutamate receptors. Mol.Pharmacol. Feb 6 Epub ahead of print PMID: 22311707
关键词: Cinnabarinic acid, Cinnabarinic acid supplier, metabotropic, glutamate, mglu4, agonists, selective, Glutamate, (Metabotropic), Group, III, Receptors, 4119, Tocris Bioscience
目前没有该产品的评论。 Be the first to review Cinnabarinic acid and earn rewards!
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.